This article is more than 5 years old. Information may no longer be current.

Institut Biochimique receives FDA clearance for OA treatment

Institut Biochimique S.A. recently received FDA approval to market GEL-SYN, a new treatment for symptoms of osteoarthritis.

An artificial material containing sodium hyaluronate — similar to hyaluronic acid found in the knee — GEL-SYN can be injected into an osteoarthritic knee joint to relieve pain stemming from osteoarthritis (OA). The product will also add extra lubrication and shock absorption to the knee joint.

The treatment consists of three weekly injections and is recommended for patients with moderate OA who have received underwhelming results from physical therapy and pain medication, according to the FDA approval overview. Treatment with GEL-SYN is expected to last up to 26 weeks. Side-effects may include injection site pain, swelling and joint pain.

For more information on this product or its clearance, please visit the FDA approval page for GEL-SYN.